Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001

• Published in: Leukemia & lymphoma 2003-01, Vol.44 (2), p.257-262
• Main Authors: Thieblemont, Catherine, Dumontet, Charles, Bouafia, Fadhela, Hequet, Olivier, Arnaud, Philippe, Espinouse, Daniel, Felman, Pascale, Berger, Françoise, Salles, Gilles, Coiffier, Bertrand
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Combined Modality Therapy; Disease Progression; Female; Gastrectomy; Gastric Lymphoma; Humans; Localized Disease; Lymphoma, B-Cell, Marginal Zone - mortality; Lymphoma, B-Cell, Marginal Zone - therapy; Male; Malt Lymphoma; Middle Aged; Prognosis; Radiotherapy; Retrospective Studies; Risk Factors; Stomach Neoplasms - mortality; Stomach Neoplasms - therapy; Survival Rate; Treatment; Treatment Outcome
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/1042819021000035680

The aim of this study was to retrospectively analyze survival and tumor response data in patients with localized gastric MALT lymphoma treated by different treatment modalities other than anti- Helicobacter pylori treatment (diagnosis made before 1993, or after failure of antibiotics+anti-acid), including surgery, chemotherapy or combined treatment. Here we studied a series of 48 patients with stage IE or IIE disease treated during the past 11 years. These patients received different treatments: chemotherapy was proposed to 19 (40%) patients; gastric surgery to 21 (43%) patients, consisting of partial gastrectomy of 7 patients and total gastrectomy in 14 patients; combined treatment to 8 (17%) patients, consisting of surgery+chemotherapy in 7 patients and surgery+chemotherapy+radiotherapy in 1 patient. At diagnosis, 85% of the patients had good PS and no B symptoms. Complete response after treatment was reached in 45 (94%) patients (chemotherapy: 84% of the patients; surgery alone: 95%; combined treatment: 100%). Progression was observed in 16 (33%) patients. No statistical difference in the survival was found among the different therapeutic modalities: 5-year overall survival year FFP survival was 81% for chemotherapy, 86% for surgery alone and 95% for combined treatment. Prognostic factors for survival were age, performance status and hemoglobin level at diagnosis. Considering the natural bias of a retrospective analysis, surgery or chemotherapy was associated with a similar outcome in patients with MALT lymphoma after antibiotics failure.